If a lung cancer carries an EGFR, ALK, or another driver alteration, targeted therapy is usually the first-line choice; for advanced disease, PD-1/PD-L1 immune checkpoint inhibitors (often combined with chemotherapy or an anti-angiogenic drug) are the other mainstay. China diagnoses more lung cancer cases than any other country, and its approved targeted and immunotherapy options rank among the world's largest — at prices that are generally far below those in the US and Europe. For many self-paying international patients, that cost gap is the most practical reason to consider treatment in China.
One thing must come first, however: any treatment plan has to be built on a confirmed pathology diagnosis and, where needed, genetic testing. If you have not yet been diagnosed, or you doubt your pathology results, the correct first step is a remote pathology review — not booking a flight. This guide walks through the availability and indicative costs of lung cancer targeted and immunotherapy in China, testing arrangements, the care pathway, and — honestly — the limitations and risks.
What China's Lung Cancer Volume Means for Patients
According to the International Agency for Research on Cancer (IARC, GLOBOCAN 2022), roughly 2.48 million new lung cancer cases were recorded worldwide in 2022, making lung cancer the most commonly diagnosed cancer and the leading cause of cancer death globally. About 1.06 million of those cases — more than 40% of the global total — occurred in China, the highest of any country.
For international patients, the practical meaning is this: the thoracic surgery, respiratory medicine, and medical oncology departments of China's major cancer centers handle first-tier global volumes of lung cancer cases every year. Familiarity with driver-gene mutation patterns, experience managing targeted-therapy resistance, and the recognition and management of immune-related side effects all come from caseload. That does not mean "any hospital will do" — quality still depends on the specific institution and team — but treatment volume is a substantive factor when weighing where to be treated.
Targeted Therapy: Driver Genes First, Drugs Second
Targeted therapy in non-small cell lung cancer (NSCLC, roughly 80–85% of lung cancers) depends on "driver genes": EGFR mutations are especially common among Asian patients and never-smokers with lung adenocarcinoma, while ALK fusions, ROS1, MET, and RET alterations each have matching drugs. Which alteration is found determines which class of drug is used.
For common classic EGFR mutations, third-generation EGFR-TKIs are now the mainstream first-line option, with first-generation drugs still used in certain situations. After resistance develops, a repeat biopsy or liquid biopsy is needed to identify the resistance mechanism (such as T790M or MET amplification) before adjusting the plan — and this kind of "re-decision after resistance" is precisely where high-volume centers excel.
EGFR-TKI Availability and Prices in China
The Chinese market is characterized by originator and domestic drugs coexisting, with most of them on the national reimbursement drug list. International patients generally cannot use Chinese insurance and self-pay at hospital pharmacy list prices, so the ranges below reflect post-negotiation list prices (confirm the actual price with the hospital pharmacy):
| Drug (generic name) | Generation | Indicative self-pay price per month |
|---|---|---|
| Gefitinib (originator and generics) | 1st | ¥1,100–1,700 (about US$150–240) |
| Icotinib (domestic) | 1st | ¥3,000–3,500 (about US$420–490) |
| Osimertinib (originator) | 3rd | about ¥15,000 (about US$2,100) |
| Aumolertinib (domestic) | 3rd | ¥5,000–6,000 (about US$700–840) |
| Furmonertinib (domestic) | 3rd | about ¥5,000 (about US$700) |
A few notes: osimertinib's price has fallen roughly 70% from its launch level since it entered the national reimbursement list in 2019, and domestic third-generation drugs have substantially lowered the entry threshold for 3rd-gen regimens. Which drug within a generation to use is an oncologist's decision based on mutation type, brain metastases, and overall condition — not price.
ALK and Other Rare Alterations
ALK fusion is often called the "diamond mutation": multiple generations of ALK inhibitors, including crizotinib and alectinib, are approved and reimbursed in China. Approved drugs also exist for ROS1 fusions, MET exon 14 skipping, and RET fusions. Rare-alteration drugs usually carry higher unit prices, but availability is rarely the problem in China — the more common bottleneck is whether the initial testing panel covered these genes, which brings us to NGS testing.
Immune Checkpoint Inhibitors: Choice and Price in One Market
As of early 2025, around 18 PD-1/PD-L1 monoclonal antibodies had been approved in China — among the most of any country. The list includes imported agents such as pembrolizumab (Keytruda), nivolumab (Opdivo), and durvalumab, alongside multiple domestic drugs including sintilimab, camrelizumab, tislelizumab, and toripalimab. A wider shelf means more workable options for patients with different comorbidities, and alternatives when supply or price becomes a problem.
The price gap is even more striking. Through successive national reimbursement negotiations — sintilimab, for example, entered the list in 2019 at roughly a 61% discount — the list prices of domestic PD-1 drugs are typically a small fraction of Western equivalents. For a lung cancer regimen that includes immunotherapy, self-paying international patients usually face annual treatment costs on the order of tens of thousands to a bit over 100,000 CNY (roughly US$7,000–15,000), whereas PD-1 therapy in the United States commonly exceeds US$100,000 per year. The exact regimen, cycle, and cost depend on the disease; treat these as order-of-magnitude references only.
Immunotherapy Is Not a Magic Bullet
To be honest, immunotherapy has boundaries:
PD-L1 expression level affects response to single-agent immunotherapy; patients with low or negative expression benefit less from it alone.
For EGFR/ALK-positive patients, single-agent immunotherapy is usually not the first choice, and the sequencing with targeted drugs needs medical assessment.
Immune-related adverse events (pneumonitis, hepatitis, endocrine disorders) are uncommon but can be serious, requiring a hospital that can manage inpatient care.
Immunotherapy responds on a different clock than chemotherapy — some patients need weeks to months before efficacy can be judged.
These are reasons to be treated at an experienced center, not reasons to assume immunotherapy is automatically better.
Genetic Testing (NGS): The Prerequisite for a Plan
Both targeted and immunotherapy choices depend on testing. Tissue samples (biopsy or surgical specimen) come first; blood-based liquid biopsy can supplement when tissue is insufficient. Most major Chinese hospitals can send samples to in-house or third-party laboratories for NGS panels, at typical price ranges:
| Test type | Coverage | Indicative self-pay price |
|---|---|---|
| Small panel | 8–20 genes | ¥3,000–6,000 (about US$420–840) |
| Large panel | hundreds of genes | ¥10,000–30,000 (about US$1,400–4,200) |
The doctor decides which test is appropriate: a small panel or even single-gene testing suffices when only the classic EGFR/ALK targets are in play; large panels are reserved for rare alterations, resistance mechanisms, or broader biomarkers. Reports usually take 1–2 weeks and should always be interpreted by a physician, not by matching your report against internet articles.
Who Should Consider Coming to China
Patients already diagnosed with NSCLC, with complete pathology and imaging records, seeking a second opinion or a more cost-effective treatment option.
Driver-gene-positive patients facing long-term targeted therapy who care about drug availability and lifetime costs.
Patients who need immunotherapy or chemo-immunotherapy but face prohibitive prices or unapproved drugs at home.
Complex cases or post-resistance situations where a high-volume center's re-decision experience matters.
Conversely, if you have not been diagnosed, or your situation is primarily supportive care, the benefit of crossing borders is usually limited — a remote consultation first is the more pragmatic move.
Care Pathway and Timeline
Remote consultation and records review: assemble pathology reports and slides, CT/MRI imaging, genetic reports, and medication history; a Chinese oncologist makes a preliminary assessment of whether coming is worthwhile.
Visa and travel: note that the 240-hour visa-free transit policy does not cover medical treatment; you should apply for the appropriate visa category.
On-site evaluation: outpatient consultation, repeat imaging, and laboratory work are usually completed within 1–3 working days.
Additional testing (if needed): NGS reports generally take 1–2 weeks; with complete reports in hand you can move straight into treatment planning.
Starting treatment: outpatient infusion or inpatient care, depending on the regimen.
Follow-up at home: coordinate with your local oncologist; some centers offer remote follow-up.
With complete records, most international patients go from arrival to starting treatment within 1–2 weeks; add time if genetic testing must be redone.
Honest Notes: Limitations and Risks
Without a confirmed pathology and genetic results, no responsible physician will issue a concrete plan remotely — "review pathology first, decide on travel second" applies to everyone.
All targeted drugs eventually face resistance, and immunotherapy carries low-probability but potentially serious adverse events. Any claim of a "guaranteed cure" for advanced lung cancer is not credible.
Cross-border treatment means follow-up is split between two countries; align with your home oncologist in advance.
All prices in this article are order-of-magnitude references from public ranges; actual costs vary by hospital, disease, and regimen.
How to Start
The most pragmatic first step is a remote second opinion: upload your pathology and imaging records, and a Chinese oncologist will assess whether the diagnosis holds, whether your current plan can be optimized, and whether coming to China makes sense. MyMedVia helps international patients connect with hospital international departments, arrange remote consultations, assist with visas and travel, provide full interpretation, and clarify itemized costs. You can submit your records through our contact page to begin.
If you are comparing advanced cancer therapies in China — proton and heavy-ion therapy, CAR-T, precision medicine — see this overview. For CAR-T's approved indications and prices, see the CAR-T therapy page and the 2026 indications guide. More articles on cancer treatment are collected on the category page.
This article is general information and does not constitute medical advice. Treatment decisions should follow your pathology and genetic testing results and your treating physician's assessment.
